TY - JOUR
T1 - 2019 clinical trials in lipid lowering
AU - Feldman, David I.
AU - Pacor, Justin M.
AU - Blumenthal, Roger S.
AU - Nasir, Khurram
N1 - Funding Information:
Dr Nasir is supported by the Jerold B. Katz Academy of Translational Research. Advisory board: Amgen, Regeneron, Medicine Company.
Publisher Copyright:
© 2020 Lippincott Williams and Wilkins. All rights reserved.
PY - 2020/7/1
Y1 - 2020/7/1
N2 - Purpose of reviewLipid-lowering therapies play a major role in reducing atherosclerotic cardiovascular disease (ASCVD). This article reviews the most recent lipid-lowering therapy trials, many of which provide a unique opportunity to further reduce low-density lipoprotein cholesterol (LDL-C) levels and ASCVD risk on top of statin therapy, and in doing so further decrease the number of future major adverse cardiovascular events.Recent findingsAlthough statin therapy has been the mainstay of treatment for lowering LDL-C levels for many years, many individuals require additional or alternative options for further reducing their risk. Trials on previously studied therapies, such as PCSK9 inhibitors, and new therapies, including inclisiran, bempedoic acid and icosapent ethyl demonstrate significant potential for further lowering of LDL-C levels and risk for events on top of maximally tolerated statin therapy with favourable side effect profiles.SummaryAs therapies for ASCVD prevention continue to emerge, clinicians will need to identify the appropriate treatment for individuals based on their estimated risk and risk-enhancing factors. When statin therapy is either not sufficient or patients do not tolerate adequate statin therapy, relying on newer therapies, such as PCSK9-inhibitors, inclisiran, bempedoic acid and icosapent ethyl, will be critical to maximize risk factor profiles to reduce adverse outcomes.
AB - Purpose of reviewLipid-lowering therapies play a major role in reducing atherosclerotic cardiovascular disease (ASCVD). This article reviews the most recent lipid-lowering therapy trials, many of which provide a unique opportunity to further reduce low-density lipoprotein cholesterol (LDL-C) levels and ASCVD risk on top of statin therapy, and in doing so further decrease the number of future major adverse cardiovascular events.Recent findingsAlthough statin therapy has been the mainstay of treatment for lowering LDL-C levels for many years, many individuals require additional or alternative options for further reducing their risk. Trials on previously studied therapies, such as PCSK9 inhibitors, and new therapies, including inclisiran, bempedoic acid and icosapent ethyl demonstrate significant potential for further lowering of LDL-C levels and risk for events on top of maximally tolerated statin therapy with favourable side effect profiles.SummaryAs therapies for ASCVD prevention continue to emerge, clinicians will need to identify the appropriate treatment for individuals based on their estimated risk and risk-enhancing factors. When statin therapy is either not sufficient or patients do not tolerate adequate statin therapy, relying on newer therapies, such as PCSK9-inhibitors, inclisiran, bempedoic acid and icosapent ethyl, will be critical to maximize risk factor profiles to reduce adverse outcomes.
KW - atherosclerotic cardiovascular disease risk
KW - cardiovascular prevention
KW - lipid-lowering therapy
KW - lipids
KW - statins
UR - http://www.scopus.com/inward/record.url?scp=85086008136&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086008136&partnerID=8YFLogxK
U2 - 10.1097/HCO.0000000000000757
DO - 10.1097/HCO.0000000000000757
M3 - Review article
C2 - 32412963
AN - SCOPUS:85086008136
SN - 0268-4705
VL - 35
SP - 319
EP - 324
JO - Current Opinion in Cardiology
JF - Current Opinion in Cardiology
IS - 4
ER -